| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | etonogestrel | FAERS: 1758 | OFFSIDES SIDER US FAERS | |
| 2 | Baclofen | FAERS: 126 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 3 | histrelin | FAERS: 18 | US FAERS | |
| 4 | Alendronate | FAERS: 4 | OFFSIDES US FAERS | |
| 5 | Buprenorphine | FAERS: 4 | US FAERS | |
| 6 | Goserelin | FAERS: 3 | US FAERS | |
| 7 | Morphine | FAERS: 3 | US FAERS | |
| 8 | Norgestrel | FAERS: 3 | US FAERS | |
| 9 | Zoledronic Acid | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 10 | rofecoxib | FAERS: 3 | US FAERS | |
| 11 | Copper | FAERS: 2 | US FAERS | |
| 12 | Tenofovir | FAERS: 2 | US FAERS | |
| 13 | ziconotide | FAERS: 2 | US FAERS | |
| 14 | Cytarabine | FAERS: 1 | US FAERS | |
| 15 | Droxidopa | FAERS: 1 | US FAERS | |
| 16 | Fluoxetine | FAERS: 1 | US FAERS | |
| 17 | Fosamax plus D | FAERS: 1 | US FAERS | |
| 18 | Glatiramer Acetate | FAERS: 1 | US FAERS | |
| 19 | Ibandronic Acid | FAERS: 1 | US FAERS | |
| 20 | Ibandronic Acid | FAERS: 1 | US FAERS | |
| 21 | Naltrexone | FAERS: 1 | US FAERS | |
| 22 | Octreotide | FAERS: 1 | US FAERS | |
| 23 | Pamidronate | FAERS: 1 | US FAERS | |
| 24 | Rosiglitazone | FAERS: 1 | US FAERS | |
| 25 | Teriparatide | FAERS: 1 | US FAERS | |
| 26 | Ticagrelor | FAERS: 1 | US FAERS | |
| 27 | carfilzomib | FAERS: 1 | US FAERS | |
| 28 | montelukast | FAERS: 1 | US FAERS | |
| 29 | Ciprofloxacin | OFFSIDES | ||
| 30 | Citalopram | OFFSIDES | ||
| 31 | Estrogens, Conjugated (USP) | OFFSIDES | ||
| 32 | Nadolol | OFFSIDES | ||
| 33 | Naltrexone | OFFSIDES | ||
| 34 | Pamidronate | OFFSIDES | ||
| 35 | Sotalol | OFFSIDES | ||
| 36 | Triazolam | OFFSIDES | ||
| 37 | chlordiazepoxide, clidinium drug combination | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.